Prof Adjei and his colleagues at the Mayo Clinic, University of Colorado Health Sciences Center and Fox Chase Cancer Center in the second part of of the patients were enrolled patients were recruited with advanced cancers, including melanoma, lung and colon cancer. Approximately 40 percent of patients had melanoma. Researchers were particularly interested in this type of tumor, since a large part may harbor B – Raf mutations and tumors with these mutations are very sensitive to MEK inhibitors.

Two patients, one with thyroid receive and the other with melanoma, continue treatment with AZD6244 after one year. Sixteen of the 20 patients with melanoma completed at least one cycle of treatment. Twelve had stable disease after completion of cycle two, with stable disease persisting for at least 5 months in six patients . Prof Adjei said: This drug shows promising results It seems to be able to cancer targeted with over activation of MEK and associated cell signaling pathways in an efficient manner Moreover, it is easy to tell the patient, as there will. Comes in an oral formulation, which can be swallowed as a result a series of phase II clinical trials in patients with melanoma, pancreatic, lung and colorectal cancer has been initiated .. Continue reading

In lab experiments.

Source: Ohio State Universityscientists have discovered a nanoparticle to make effective genetic material into cells with minimal toxic effects seems.In lab experiments , the researchers determined that this machine , a vector in a position to deliver DNA deeply enough into a cell to genetic material to be – a critical step – a critical step in gene therapy. This vector is between 2? and 10 – times more potent than other experimental materials, according to the research.

The study also showed that this hybrid particle receive its structure for at least 21 days and, when combined with a variety of other potential vector substances in comparison, has very little damage to cells, ie it is not as toxic as the most other materials. Continue reading